The period in summary
Figures in brackets indicate outcome for the corresponding period of the previous financial year. The financial information presented relates to the Group and is expressed in TSEK unless otherwise stated.
Group key ratios
01/10/20 01/10/19 Full year Full year
-31/12/20 -31/12/19 2020 2019
Net sales 943 1 079 4 780 12 139
Operating result -7 163 -7 829 -25 676 -27 848
Result after -7 094 -7 851 -25 601 -27 892
Balance sheet total 355 282 237 067 355 282 237 067
Equity ratio 95% 93% 95% 93%
Number of shares 50 160 388 43 292 690 50 160 388 43 292 690
outstanding end of
Average number of 50 160 388 43 292 690 47 008 659 39 228 377
Average number of 50 359 877 43 524 383 47 141 055 39 336 557
shares after dilution
Earnings per share -0,14 -0,18 -0,54 -0,71
Earnings per share -0,14 -0,18 -0,54 -0,71
Net sales during the fourth quarter of 2020 amounted to SEK 0.9 million, which is a decrease of SEK 0,1 million compared to the same period in 2019. For the fiscal year 2020 the sales decrease is approx. SEK 7.3 million, from SEK 12.1 million during 2019 to SEK 4.8 million during 2020. The lower sales are mainly due to that the new products in the distribution portfolio are in a launch and establishment phase.
Operating result for the fourth quarter of 2020 amounted to SEK -7.2 million, which is a increase of SEK 0.6 million compared to the same period in 2019 (-7.8). For 2020 the operating result is approx. SEK -25.7 million, which is approx. SEK 2.1 million better than during last year (-27.8). The negative operating result is mainly explained by the fact that the Group does not generate sufficient funds from its own operations to finance the vaccine development.
The directed share issue in June together with the use of employee stock options and warrants from the incentive programs from 2017 during May and July has increased available cash with net approx. SEK 143.4 million. During 2020 SEK 10.4 million have been invested in Strangvac capitalized expenditure which is a decrease with SEK 28.2 million compared to same period during 2019 (SEK 38.6 million). Cash flow during fourth quarter has meant that cash has decreased with SEK 7.4 million and amounts to SEK 164.3 at the end of 2020.
At the end of 2020 equity amounted to SEK 337.6 million, which compared to the same date last year is an increase with SEK 117.8 million. Approx. 42% (59%) of the group's total assets has been invested in capitalized expenditure which at end of 2020 amounts to SEK 149.3 million. Cash, which at end of 2020 amounts to SEK 164.3 million, are greatly affected by the investments made in research and development, where our new and ongoing projects become more and more essential. It also includes, for example, the upcoming regulatory process with the USDA (US Department of Agriculture), and technology transfer for the US market. The company is well equipped for continued commercialization and vaccine development.
Vaccines in the spotlight
Covid-19 has made a big impact on our daily lives and during the past year, vaccine development, the European Medicines Agency (EMA), regulatory processes and vaccine manufacturing have received a lot of attention. What we work with every day has become interesting for everyone and developing new effective vaccines is very much on the agenda!
We are in an intensive phase of preparations for the market launch of Strangvac, our vaccine against the equine disease strangles. During the second half of 2020, we worked on the so-called day 120 questions that we received from EMA. We strengthened the dossier where needed and on 12th of January this year we submitted our answers. On January 18th, EMA confirmed that they had received our response and accepted that we had submitted them correctly and on time. The regulatory team, together with our researchers, have done a fantastic job!
On January 19th, the clock re-started at day 121 in the evaluation process. The next stop is day 180, when we expect further constructive interactions with EMA. We are on-track for a positive opinion from EMA during the second quarter of this year after which, the European Commission has up to 67 days to give its formal approval. With that comes the market launch of Strangvac in Europe. The work of choosing a distribution partner for the countries in Europe where we do not distribute ourselves is steadily progressing. In November, we recruited Emma Hartman in the role of global product manager with responsibility for launching Strangvac. Emma comes most recently from MSD Animal Health, where she worked as product manager for equine and cattle, and her experience from having worked for one of the largest global suppliers of equine vaccines is very valuable for us. We have been working closely with important key opinion leaders for a long time and through the recruitment of Dr Andrew Waller this summer that network was further strengthened. We have a product, a network, and a team to deliver success!
In parallel with the regulatory work towards approval of Strangvac in Europe, we are also working to obtain approval to sell Strangvac in the USA, a market that is approximately 50% larger than the European market. Together with local expertise, we are developing a plan to be shared with the Centre for Veterinary Biologics (CVB), which is part of the United States Department of Agriculture (USDA). The dialogue with CVB will clarify the extent of local studies needed in the US approval process, but it is clear that this process will benefit greatly from the trials and regulatory work we have already completed for our application to EMA.
We already have almost 60,000 doses produced for the launch of Strangvac and we are planning for further production together with our partners Liof Pharma and 3P Biopharmaceuticals in Spain. An important part of the preparations for vaccine production and distribution is the recruitment of Astrid Larberg in the role of quality assurance manager. She joins us from AstraZeneca and is not only a biologist and quality expert but is also a trained veterinarian. Astrid starts on the first of March and we look forward to welcoming her into the team and the role!
We are making progress in our preclinical trials for new vaccines in addition to Strangvac. The vaccine projects that are most advanced target infections caused by Streptococcus suis in piglets following weaning, and Staphylococcus aureus which, among other diseases, is an important cause of mastitis in dairy cows. In both projects, we are conducting small-scale trials in the target animal.
The transition of our Nordic distribution operations to new products in strategic segments continues. The pharmaceutical product from Syva that we launched during the autumn in the cattle and pig segments has got off to a good start. The drug for the treatment of hypocalcemia and hypomagnesemia conditions in cattle, for which we are the Market Authorization Holder (MAH), also shows good growth in both Sweden and Denmark. The business is still relatively small, but with good conditions for growth it forms a solid foundation for sales of our in-house developed vaccines. In February 2021, we launched two new products from the AnimalCare Group, both in the dog and cat segment.
Our veterinary laboratory in bacteriology, where we offer services to veterinary clinics around Sweden, showed over 35% growth during the full year. The growth came mainly in the equine segment, which is strategically important to us. The Veterinary Laboratory gives us proximity to our customers, and thanks to the influx of samples we have a direct and reliable source of information to understand how various bacterial infectious diseases develop in animals in Sweden and the potential impact of new vaccines towards improving the health of animals.
2020 was a fantastic year for Intervacc and 2021 will be the year when we launch our first proprietary vaccine, Strangvac. This is something we are all looking forward to and I would like to take this opportunity to thank all employees, partners and shareholders.
Andreas Andersson CEO
Significant events during the period
October 1 - December 31, 2020
Intervacc appointed Emma Hartman as Global Product Manager for Strangvac
Emma Hartman was appointed to the role as global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease strangles. Emma Hartman has a DVM degree and most recently comes from MSD Animal Health, where she held the position as Nordic product manager for equine and ruminant products.
Significant events after the period
Intervacc has submitted Responses to EMA Day 120 Questions
On January 12[th] Intervacc submitted the responses to the Day 120 questions regarding the Company's Marketing Authorization Application (MAA) for Strangvac to the European Medicines Agency (EMA). Intervacc is seeking approval for Strangvac as a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally.
On January 18[th] EMA accepted the submission and after reviewing the responses, a second list of questions and outstanding issues is expected from the Committee for Medicinal Products for Veterinary Use (CVMP). The Company estimates that it is on track for a positive opinion from the CVMP during Q2 2021.
Eminova Fondkommission is Intervacc's Certified Adviser and is responsible for the company's compliance with Nasdaq First North Growth Markets regulations.
Eminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
114 46 Stockholm
Tel: +46 8 684 211 10
The Board of Directors proposes that no dividend be paid.
Dates for upcoming reports
May 21, 2021 Interim report Q1 January 1 - March 31, 2021
September 3, 2021 Interim report Q2 January 1 - June 30, 2021
November 11, 2021 Interim report Q3 January 1 - September 30, 2021
February 18, 2022 Year-end report January 1 - December 31, 2021
Annual report 2020 will be published on March 31, 2021 on the company's website.
Annual General Meeting
Annual General Meeting 2021will take place on June 9, 2021.
Andreas Andersson, CEO
Phone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70
The full year-end report for the period January - Deptember 2020 is attached to this press release and is available on the company's website www.intervacc.se.
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on February 18, 2021.
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017.
This information was distributed by Cision http://www.cisionwire.se/